Sandu Pharmaceuticals Ltd. said its normalized net income for the fiscal first quarter ended June 30 was 9 Indian paise per share, a decline of 25.0% from 13 paise per share in the year-earlier period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 651,880 rupees, a decrease of 26.8% from 890,000 rupees in the year-earlier period.
The normalized profit margin dropped to 0.8% from 1.2% in the year-earlier period.
Total revenue increased 9.7% on an annual basis to 82.7 million rupees from 75.4 million rupees, and total operating expenses increased 8.9% year over year to 78.5 million rupees from 72.1 million rupees.
Reported net income totaled 1.1 million rupees, or 16 paise per share, compared to 1.1 million rupees, or 16 paise per share, in the year-earlier period.
As of Aug. 14, US$1 was equivalent to 60.85 Indian rupees.